Upgrade to SI Premium - Free Trial

CSLLY (CSLLY)

32.21 +0.68 (2.16%)

Chart
Today 6M 1Y 5Y

Latest Headlines

CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases October 4, 2026 5:42 PM - PR NewsWire CSL Seqirus Expands U.S. Availability of Influenza Vaccine following Successful Completion of the 2026/27 Manufacturing Campaign September 29, 2026 9:30 AM - PR NewsWire CSL Ltd. (CSL:AU) (CSLLY) PT Raised to AUD182.50 at Goldman Sachs September 28, 2026 2:24 AM - StreetInsider Lancet Publication Marks Important Advance in Influenza Prevention for Older Adults September 10, 2026 6:40 PM - PR NewsWire CSL Ltd. (CSL:AU) (CSLLY) PT Raised to AUD160 at Citi August 20, 2026 7:24 AM - StreetInsider CSL Ltd. (CSL:AU) (CSLLY) PT Raised to AUD181 at UBS August 19, 2026 3:21 AM - StreetInsider CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE) July 27, 2026 9:00 AM - PR NewsWire Full Article List